GlobeNewswire PharmaOriginal article
Ubamatamab (MUC16xCD3) Shows a High Rate of Durable Responses in Initial Study of Patients with Advanced Low-Grade Serous Ovarian Cancer (LGSOC)
Data ReadoutpositiveUbamatamabPositive
AI Analysis
Summary
Ubamatamab (MUC16xCD3) demonstrated a high rate of durable responses in an initial study of patients with advanced low-grade serous ovarian cancer, an indication with limited treatment options and poor response to conventional chemotherapy.
Clinical Trial Data
Primary Endpoint
Met
Outcome Details
High rate of durable responses in initial study of patients with advanced LGSOC
Importance:6/10
Sentiment:
0.70
oncologyovarian cancerbispecific antibodyclinical datarare indication
Read the original article
Published by GlobeNewswire Pharma on October 1, 2026 3:35 PM